{"filing":{"accession_number":"0001648257-26-000053","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"hcm-20260828x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000053/hcm-20260828x6k.htm"},"events":[{"id":30164,"run_id":27646,"accession_number":"0001648257-26-000053","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces NMPA (China National Medical Products Administration) conditional approval of ATLED® (fanregratinib) for treating FGFR2-altered intrahepatic cholangiocarcinoma. This is a material regulatory milestone and product approval event that does not fit the specific `earnings_release` category (no financial results disclosed) nor other named event types. The approval represents a significant operational and commercial achievement for the company's drug development pipeline, supported by Phase II trial data meeting primary endpoints (42.5% ORR). This would materially affect a reasonable investor's assessment of the company's commercial prospects and pipeline value.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-08-28","form":"6-K","submitted_at":null,"items":[{"id":32689,"accession_number":"0001648257-26-000053","item_number":"EX-99.1","item_title":"hcm-20260828xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces NMPA (China National Medical Products Administration) conditional approval of ATLED® (fanregratinib) for treating FGFR2-altered intrahepatic cholangiocarcinoma. This is a material regulatory milestone and product approval event that does not fit the specific `earnings_release` category (no financial results disclosed) nor other named event types. The approval represents a significant operational and commercial achievement for the company's drug development pipeline, supported by Phase II trial data meeting primary endpoints (42.5% ORR). This would materially affect a reasonable investor's assessment of the company's commercial prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:22:39.952892+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32689,"accession_number":"0001648257-26-000053","item_number":"EX-99.1","item_title":"hcm-20260828xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces NMPA (China National Medical Products Administration) conditional approval of ATLED® (fanregratinib) for treating FGFR2-altered intrahepatic cholangiocarcinoma. This is a material regulatory milestone and product approval event that does not fit the specific `earnings_release` category (no financial results disclosed) nor other named event types. The approval represents a significant operational and commercial achievement for the company's drug development pipeline, supported by Phase II trial data meeting primary endpoints (42.5% ORR). This would materially affect a reasonable investor's assessment of the company's commercial prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:22:39.952892+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-08-28"}]}